Market Outlook

By 2035, the U.S. Connected Neurology Devices Market is expected to reach approximately USD 17.09 billion, expanding at a CAGR of 13.40% during the forecast period from 2026 to 2035. The market was valued at an estimated USD 4.86 billion in 2025, with historical analysis covering 2021 to 2024. Values in this report are expressed in USD billions.

For the purpose of this report, connected neurology devices include regulated neurological diagnostic, monitoring, therapeutic, neurostimulation, neurorehabilitation, and assistive devices capable of transmitting physiological information, exchanging programming data, synchronizing with a clinical platform, supporting remote intervention, or enabling cloud-based neurological analysis. The market includes device-associated sensors, patient controllers, clinical programmers, connectivity hubs, embedded software, and directly linked monitoring services. It excludes general-purpose consumer wearables without neurological medical claims, standalone telehealth platforms, pharmaceuticals, conventional non-connected neurological equipment, and wellness applications.

The market expanded from approximately USD 2.80 billion in 2021 to USD 4.22 billion in 2024. Growth during the historical period was supported by the normalization of neurology procedures after pandemic-related disruption, higher utilization of ambulatory electroencephalography, expansion of remote deep brain stimulation programming, increased adoption of point-of-care EEG systems, and growing commercial interest in digital biomarkers for epilepsy, Parkinson’s disease, stroke, and neurodegenerative disorders.

The U.S. connected neurology device industry is moving from episodic neurological testing toward continuous, longitudinal, and increasingly personalized disease management. Traditional neurology workflows depend heavily on periodic clinic visits, subjective patient reporting, short-duration diagnostic tests, and specialist interpretation. Connected devices are changing this model by capturing neurological information between visits, transmitting data to clinicians, identifying clinically relevant changes, and enabling therapy adjustments without requiring every interaction to occur inside a tertiary medical center.

The addressable patient population is substantial. Approximately 2.9 million U.S. adults and more than 450,000 children are estimated to have active epilepsy. More than 795,000 strokes occur in the United States each year. More than 6 million Americans age 65 and older are estimated to have Alzheimer’s disease, while Parkinson’s disease affects close to 1 million people nationally. These conditions generate sustained demand for EEG monitoring, seizure detection, implantable neurostimulation, movement analysis, cognitive assessment, neurorehabilitation, and post-discharge neurological surveillance.

Unlike conventional neurology equipment markets, connected neurology devices create value through both physical technology and recurring clinical interaction. A connected device can generate revenue from the original hardware sale, implant procedure, software license, disposable sensor, remote programming session, data review, service agreement, or recurring monitoring workflow. This structure is attracting established medtech companies, specialist neurological device manufacturers, digital health developers, hospital technology vendors, and venture-backed neurotechnology companies.

The market values presented in this report are analyst-derived estimates based on procedure volumes, installed device populations, U.S. product revenues, average selling prices, replacement cycles, connected software attachment rates, and adoption across hospitals, neurology practices, rehabilitation providers, and home-monitoring programs. The model does not apply valuations from the reference market and has been developed specifically for the commercial structure of the U.S. Connected Neurology Devices Market.

 

Introduction

According to the U.S. Connected Neurology Devices Market Report, neurological care in the United States is entering a period of structural change driven by aging demographics, specialist access constraints, rapid device innovation, improved wireless connectivity, and growing pressure to manage chronic neurological diseases outside high-cost hospital environments.

Neurological disorders are particularly suited to connected-device models because symptoms can fluctuate substantially between office visits. Seizures, tremor severity, gait instability, medication-related motor changes, cognitive decline, sleep disruption, and post-stroke functional performance may be difficult to characterize through a short clinical encounter. Connected devices provide clinicians with a larger and more representative body of longitudinal information.

The market includes several distinct commercial models. Connected implantable systems such as deep brain stimulation, responsive neurostimulation, and vagus nerve stimulation devices generate high revenue per patient and require long-term programming and follow-up. EEG and neurodiagnostic systems combine capital equipment, disposable electrodes, software, and remote interpretation. Wearable neurological devices generate repeated data through sensors used in the home. Neurorehabilitation systems combine robotics, functional electrical stimulation, motion analysis, and therapeutic software. Emerging brain-computer interfaces connect neural signals to computers, communication tools, mobility devices, or rehabilitation systems.

Hospital procurement decisions are therefore influenced by more than device acquisition cost. Buyers evaluate diagnostic turnaround time, neurologist workload, nursing requirements, ease of implementation, compatibility with electronic health records, cybersecurity controls, data ownership, reimbursement availability, and the ability to reduce avoidable emergency department utilization or hospital admissions.

Connected neurology devices are also changing the geographic economics of neurological care. Advanced epilepsy, movement-disorder, and neurostimulation expertise remains concentrated in academic and metropolitan medical centers. Patients in rural or underserved areas may travel several hours for specialist assessment or device programming. Remote neurological monitoring and tele-programming can reduce travel requirements, improve follow-up adherence, and allow regional hospitals to participate in care pathways led by tertiary neuroscience centers.

From 2026 to 2035, competition will increasingly favor manufacturers that can connect diagnosis, treatment, monitoring, and clinical decision support within a single neurological workflow. Companies offering isolated hardware will face pressure from platforms that combine devices with remote access, automated prioritization, interoperable data, longitudinal outcomes, and service-line economics.

 

Key Market Drivers: What’s Fueling the U.S. Connected Neurology Devices Market Boom?

The first major driver is the scale and chronic nature of neurological disease in the United States. Neurological conditions frequently require years of monitoring rather than a single intervention. Epilepsy patients may need repeated EEG evaluation and seizure surveillance. Parkinson’s disease patients require ongoing assessment of tremor, rigidity, bradykinesia, gait, medication response, and stimulation settings. Stroke survivors may need extended rehabilitation and recurrent functional evaluation. Patients with cognitive impairment require longitudinal assessment that can distinguish temporary variation from progressive decline.

This chronicity supports connected-device economics. A conventional diagnostic procedure produces a limited clinical snapshot, while a connected platform can extend observation over hours, days, months, or years. Manufacturers are consequently developing devices that generate repeated clinical touchpoints rather than one-time transactions.

The second driver is limited access to neurological specialists. The United States has a sophisticated neuroscience infrastructure, but access is uneven. Board-certified neurologists, epileptologists, movement-disorder specialists, neurophysiologists, and functional neurosurgeons remain concentrated in larger metropolitan markets and academic systems. Rural patients may experience delayed diagnosis, long travel distances, and inconsistent follow-up. Connected EEG, remote device programming, cloud-based neurological review, and wearable monitoring allow specialist expertise to be extended beyond the physical boundaries of major neuroscience centers.

The third driver is the transition from subjective symptom reporting to objective digital measurement. Many neurological treatment decisions still depend on patient diaries, caregiver observations, retrospective recall, and intermittent physical examination. These approaches can underestimate nocturnal seizures, short motor fluctuations, freezing-of-gait events, subtle tremor progression, or changes in daily function.

Wearable accelerometers, surface electrophysiology, EEG sensors, connected patient controllers, and digital motor assessments can produce quantitative measures of neurological status. The commercial value of these technologies is highest when their output changes treatment decisions rather than merely generating additional data. Devices that can distinguish clinically meaningful deterioration from normal variation are likely to gain preference over high-volume data systems that create additional review burden.

The fourth driver is rapid development of connected neuromodulation. Deep brain stimulation is evolving from manually programmed, fixed-output therapy toward sensing-enabled and adaptive stimulation. Responsive neurostimulation already uses detected brain activity to guide therapy for selected epilepsy patients. Connected vagus nerve stimulation systems allow therapy management and data review over extended treatment periods. Remote programming capabilities reduce dependence on repeated in-person visits and create stronger links between implanted hardware and longitudinal care platforms.

FDA approval of adaptive deep brain stimulation in 2025 marked an important transition for the market. Adaptive systems can adjust stimulation in response to detected neural activity rather than operating only through static settings. This creates opportunities for more personalized therapy while increasing the importance of sensing algorithms, data quality, clinician training, and post-implant software support.

The fifth driver is the expansion of point-of-care and rapid-response neurodiagnostics. Conventional EEG availability can be constrained by technologist staffing, equipment setup time, neurologist interpretation capacity, and competition for hospital resources. These constraints are especially important in intensive care units and emergency departments, where delayed recognition of non-convulsive seizures can affect treatment decisions.

Portable connected EEG platforms are designed to reduce setup complexity and deliver neurological information closer to the bedside. Cloud connectivity can allow neurologists to review data from another location, while artificial intelligence can prioritize recordings with suspected seizure activity. This does not eliminate the need for clinical interpretation, but it can change the speed and economics of the diagnostic workflow.

The sixth driver is increasing payer recognition of remote monitoring. Medicare broadly covers remote physiologic monitoring for qualifying acute and chronic conditions when program requirements are met. Neurology has adopted these models more slowly than cardiology and diabetes care because neurological endpoints can be harder to standardize. However, connected neurological devices are becoming better positioned as manufacturers develop validated measures, reliable data transmission, actionable clinician dashboards, and documented care-management workflows.

The commercial opportunity depends on more than the existence of reimbursement codes. Providers must be able to identify eligible patients, obtain consent, deploy the device, review incoming information, document clinical interaction, and manage billing compliance. Device companies that provide workflow implementation and reimbursement support can therefore create greater value than companies offering hardware alone.

The seventh driver is hospital pressure to improve neurological service-line efficiency. U.S. hospitals face shortages of EEG technologists, neurologists, rehabilitation professionals, and experienced neuroscience nurses. Technologies that reduce setup time, prioritize high-risk patients, support remote interpretation, or allow therapy adjustments without repeated travel can help health systems use scarce personnel more effectively.

The economic argument is strongest when a connected device affects a measurable operational outcome. Examples include reducing the time to EEG acquisition, shortening intensive-care monitoring delays, preventing an unnecessary patient transfer, improving implanted-device follow-up, increasing therapist productivity, or detecting neurological deterioration before an emergency admission.

The eighth driver is the rising importance of home-based neurological care. Many neurological patients are older, mobility-limited, cognitively impaired, or dependent on caregivers. Frequent travel to specialty clinics can be clinically and economically burdensome. Connected monitoring, remote stimulation programming, home EEG, wearable movement tracking, and app-linked neurorehabilitation can shift portions of care into the home while maintaining specialist oversight.

The ninth driver is investment in artificial intelligence and digital biomarkers. EEG interpretation, seizure detection, movement analysis, neuroimaging support, cognitive measurement, and rehabilitation tracking are increasingly supported by machine-learning models. The most commercially valuable algorithms are being embedded into regulated devices or used as components of clinician-supervised workflows.

Artificial intelligence is unlikely to replace specialist judgment in complex neurological care. Its primary market role through 2035 will be workflow amplification: identifying high-priority recordings, quantifying patterns, reducing review time, standardizing measurements, and helping clinicians manage larger monitored populations.

The tenth driver is the maturation of the U.S. neurotechnology ecosystem. The country has a high concentration of academic neuroscience programs, clinical-trial networks, medical-device companies, artificial-intelligence developers, venture investors, and specialized regulatory expertise. This combination supports development in adaptive stimulation, minimally invasive neural interfaces, implantable cortical electrodes, wearable seizure monitoring, and brain-computer interfaces.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. connected neurology device market is focused on transforming neurological signals into clinically actionable decisions. The next competitive cycle will not be defined solely by who captures the most data. It will be defined by who can acquire reliable signals, interpret them efficiently, integrate them into the care pathway, and demonstrate improvement in outcomes or resource utilization.

Adaptive neuromodulation is one of the most important innovation areas. Conventional deep brain stimulation generally delivers stimulation according to clinician-programmed settings. Adaptive systems introduce sensing capabilities that can respond to changes in neural activity. This creates the potential for more personalized stimulation, fewer periods of over- or under-stimulation, and better management of changing symptoms.

Remote programming is another major advance. Neuromodulation patients frequently require several programming sessions, especially after implantation or during disease progression. Travel can be difficult for patients with Parkinson’s disease, essential tremor, dystonia, or advanced mobility impairment. Secure remote programming allows qualified clinicians to evaluate patients and adjust compatible systems without requiring every session to occur at an implanting center.

Connected epilepsy management is developing across diagnostic and therapeutic categories. Portable EEG systems can accelerate assessment in emergency and critical-care environments. Wearable devices can alert caregivers to selected seizure patterns. Responsive neurostimulation systems can detect abnormal electrical activity and deliver treatment. Cloud-based platforms can consolidate EEG, event, therapy, and patient-reported information.

The strongest epilepsy platforms will connect several stages of care. A patient may be identified through ambulatory monitoring, evaluated by an epilepsy center, treated with an implantable device, and followed through remote data transmission. Companies that participate across this pathway can generate more durable commercial relationships than vendors serving only one diagnostic episode.

AI-supported EEG analysis is also advancing. Automated tools can flag potential seizures, estimate seizure burden, classify abnormalities, and prioritize recordings for specialist review. These systems are particularly relevant for hospitals that lack continuous on-site neurophysiology coverage. The commercial advantage comes from faster escalation and more efficient use of neurologist time rather than from algorithmic output in isolation.

Movement-disorder monitoring is moving beyond clinic-based rating scales. Wearable sensors can quantify tremor, bradykinesia, dyskinesia, gait, activity, and motor fluctuations across the patient’s normal daily environment. This may help clinicians evaluate whether medication or stimulation settings are producing consistent benefit throughout the day.

However, adoption will depend on data interpretability. Movement-disorder specialists are unlikely to adopt systems that produce large volumes of non-prioritized data. Manufacturers must translate sensor outputs into clinically relevant summaries, trend changes, threshold alerts, and treatment-response measures.

Connected neurorehabilitation is another important innovation category. Robotic rehabilitation systems, functional electrical stimulation, instrumented gait devices, smart orthoses, and interactive therapy platforms can document repetitions, range of motion, adherence, force generation, and functional progress. These capabilities support a shift from session-based rehabilitation billing toward measurable recovery pathways.

Brain-computer interfaces represent the most technologically ambitious area of the market. Implanted and non-invasive BCI systems are being developed to restore communication, computer access, mobility, or sensory function for people with paralysis and other severe neurological impairments. Most implanted BCI technologies remain investigational and are not fully included in the current commercial market base. Nevertheless, FDA guidance, early feasibility studies, and new neural-interface clearances indicate that the category is progressing toward broader clinical commercialization.

Cybersecurity is becoming a core product-design requirement. Connected neurology devices can transmit sensitive physiological information and, in some cases, support changes to implanted therapy. Manufacturers must maintain secure authentication, software inventories, vulnerability management, update mechanisms, access controls, and postmarket monitoring. Cybersecurity performance will increasingly influence FDA review, hospital procurement, enterprise contracting, and clinician confidence.

Interoperability is also gaining strategic importance. Neurology departments do not want isolated portals for every device category. Health systems increasingly expect data to integrate with electronic health records, imaging archives, remote-monitoring workflows, and identity-management systems. Manufacturers that provide usable interfaces and reduce duplicate documentation will have an advantage in enterprise purchasing.

 

Segmentation Insights

The U.S. Connected Neurology Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

Connected Implantable Neuromodulation Devices

Connected implantable neuromodulation devices represented the largest product category in 2025, accounting for an estimated USD 1.76 billion, or approximately 36% of market revenue. This segment includes connected deep brain stimulation systems, responsive neurostimulation systems, vagus nerve stimulation devices, implantable cortical stimulation platforms, sensing-enabled neurostimulators, patient controllers, clinician programmers, and associated remote-management systems.

The category generates high value per patient because it combines implantable hardware, surgical components, programming systems, replacement cycles, and long-term follow-up. Growth will be driven by adaptive stimulation, smaller rechargeable devices, improved battery performance, remote programming, expanded indications, and greater use of sensing data to personalize therapy.

Deep brain stimulation for Parkinson’s disease, essential tremor, dystonia, and selected other movement disorders remains the largest commercial component. Responsive neurostimulation and connected vagus nerve stimulation provide additional growth in drug-resistant epilepsy. By 2035, connected implantable neuromodulation is expected to remain the largest revenue category, although wearable monitoring and software-enabled diagnostics will grow faster.

Connected Neurodiagnostic and Monitoring Systems

Connected neurodiagnostic and monitoring systems generated approximately USD 1.48 billion in 2025. This segment includes hospital EEG systems, ambulatory EEG equipment, point-of-care EEG, electromyography systems, evoked-potential equipment, intraoperative neurophysiological monitoring systems, cerebral-function monitors, connected neurovascular diagnostics, electrodes, amplifiers, data transmitters, and remote-review platforms.

The segment is supported by high diagnostic demand across epilepsy, critical care, sleep-related neurological conditions, neuromuscular disorders, stroke, traumatic brain injury, and surgical monitoring. Cloud connectivity allows data to be reviewed across facilities, while AI-assisted prioritization can reduce the delay between acquisition and specialist assessment.

Recurring revenue is generated through disposable electrodes, headbands, sensor arrays, software subscriptions, service agreements, and data-management platforms. Point-of-care EEG is expected to record particularly strong growth because it addresses a clear hospital workflow constraint: the delay and complexity associated with deploying conventional EEG in emergency and critical-care environments.

Wearable Neurological Monitoring Devices

Wearable neurological monitoring devices accounted for an estimated USD 0.87 billion in 2025. This category includes seizure-detection wearables, movement-disorder sensors, tremor monitors, gait and balance devices, wearable EEG systems, connected cognitive-assessment devices, sleep-neurology wearables, and digital biomarker platforms linked to regulated medical-device workflows.

The segment is expected to record one of the fastest growth rates through 2035 because it extends neurological observation into the patient’s normal environment. Wearables can capture events that may not occur during a clinic visit and can reduce dependence on retrospective symptom diaries.

Commercial adoption will depend on sensor accuracy, patient adherence, battery life, comfort, false-alert rates, and the ability to connect outputs to a defined clinical action. Devices that are reimbursable, prescribed by specialists, and integrated into care pathways will outperform direct-to-consumer products with limited medical differentiation.

Connected Neurorehabilitation and Assistive Devices

Connected neurorehabilitation and assistive devices represented approximately USD 0.44 billion in 2025. The segment includes robotic rehabilitation systems, functional electrical stimulation devices, connected exoskeletons, smart orthoses, instrumented gait systems, upper-extremity rehabilitation devices, neuroprosthetic interfaces, and rehabilitation platforms that transmit therapy or performance data.

Stroke is the primary commercial application, but demand also comes from spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy, peripheral nerve injury, and other conditions associated with motor impairment. Connected systems allow clinicians to measure therapy intensity and functional progression more consistently than traditional documentation alone.

The market is shifting toward devices that can be used across inpatient rehabilitation, outpatient therapy, skilled nursing, and the home. Portable systems with clinician dashboards and patient-engagement tools are likely to gain share as providers seek to extend therapy beyond scheduled facility visits.

Software-Enabled Neurology Platforms and Connectivity Components

Software-enabled neurology platforms and connectivity components generated approximately USD 0.31 billion in 2025. This segment includes device-linked clinical software, AI-enabled neurophysiological analysis, remote device-management platforms, data gateways, interoperable neurological dashboards, digital biomarker engines, cybersecurity services, and subscription components directly connected to regulated neurological devices.

Although this is the smallest product category by direct revenue, it is expected to exert a disproportionate influence on device selection. Hardware vendors increasingly use software to differentiate otherwise comparable systems, strengthen customer retention, support remote services, and create recurring revenue.

Growth will be strongest among platforms that reduce clinical review time, combine multiple data sources, support enterprise deployment, and generate information that can be documented within reimbursable care.

 

By Application

Epilepsy and Seizure Management

Epilepsy and seizure management was the largest application segment in 2025, generating an estimated USD 1.51 billion. The category includes connected EEG systems, ambulatory seizure monitoring, point-of-care EEG, responsive neurostimulation, vagus nerve stimulation, seizure-detection wearables, event-alert systems, and cloud-based data review.

The commercial opportunity is supported by the large epilepsy population and the difficulty of capturing intermittent events through conventional clinic visits. Hospital demand is strongest in emergency departments, intensive care units, epilepsy monitoring units, pediatric centers, and comprehensive epilepsy programs.

Growth will be driven by faster bedside EEG deployment, AI-supported seizure prioritization, longer-duration home monitoring, expanded use of implantable therapy, and greater integration of diagnostic and therapeutic data.

Movement Disorders

Movement disorders represented an estimated USD 1.22 billion in 2025 and are expected to be among the fastest-growing applications through 2035. Parkinson’s disease, essential tremor, dystonia, and other movement disorders require repeated assessment and individualized treatment.

Connected deep brain stimulation systems account for the largest share of revenue. Wearable movement sensors, remote programming, adaptive stimulation, gait analysis, and digital motor assessments are expanding the market beyond implant procedures.

The application has strong economic potential because patients may require years of device follow-up. Manufacturers that simplify programming and demonstrate stable symptom control can improve both clinical value and specialist productivity.

Stroke and Neurocritical Care

Stroke and neurocritical care accounted for approximately USD 0.87 billion in 2025. Relevant devices include rapid EEG, cerebral-function monitoring, connected intracranial monitoring, neurological deterioration surveillance, neurovascular monitoring, rehabilitation technologies, gait systems, and post-discharge recovery devices.

The United States records more than 795,000 strokes annually, creating sustained demand across emergency diagnosis, inpatient monitoring, rehabilitation, and secondary prevention. Connected technologies can support early recognition of neurological changes, remote specialist review, and more objective measurement of functional recovery.

The opportunity is particularly strong for devices that reduce treatment delays, help hospitals manage patients without immediate on-site neurological expertise, or extend rehabilitation into the home.

Neurodegenerative and Cognitive Disorders

Neurodegenerative and cognitive disorders generated an estimated USD 0.68 billion in 2025. The segment includes devices used to monitor Parkinson’s disease, Alzheimer’s disease, dementia, multiple sclerosis, amyotrophic lateral sclerosis, and related progressive conditions.

Connected technologies are used to assess movement, speech, cognition, sleep, activity, medication response, and functional decline. The market remains less mature than epilepsy monitoring or implantable neuromodulation because many digital endpoints are still being validated.

Long-term growth will be supported by the aging U.S. population, disease-modifying therapeutic development, decentralized clinical trials, and the need to measure progression outside specialist visits.

Paralysis, Neurological Rehabilitation, and Other Applications

Paralysis, neurological rehabilitation, and other applications accounted for approximately USD 0.58 billion in 2025. This segment includes connected systems for spinal cord injury, traumatic brain injury, cerebral palsy, neuromuscular disease, peripheral nerve impairment, and severe communication disability.

Functional electrical stimulation, robotic rehabilitation, eye-tracking communication, connected assistive technologies, and brain-computer interfaces are important development areas. The segment is expected to become more commercially significant as investigational neural interfaces progress toward defined clinical indications.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and integrated health systems were the dominant end users, accounting for approximately USD 2.33 billion in 2025. They purchase high-value implantable devices, EEG systems, neurocritical-care monitoring, intraoperative neurophysiology equipment, rehabilitation technology, and enterprise software.

Large health systems increasingly standardize neurological technology across multiple facilities. Procurement committees evaluate clinical performance, cybersecurity, implementation requirements, service reliability, reimbursement, and total cost per episode. Manufacturers capable of supporting multi-hospital deployments and integrated data governance are positioned to secure larger contracts.

Academic Neuroscience and Specialty Neurology Centers

Academic neuroscience and specialty neurology centers represented approximately USD 1.02 billion in 2025. These institutions are early adopters of adaptive stimulation, responsive neurostimulation, advanced EEG analytics, brain-computer interfaces, and complex neurorehabilitation systems.

They also conduct clinical trials, train specialists, publish evidence, and influence national adoption. Commercial success in this channel can support broader penetration into regional and community health systems.

Ambulatory Neurology Practices and Diagnostic Centers

Ambulatory neurology practices and diagnostic centers generated approximately USD 0.63 billion in 2025. Demand is concentrated in ambulatory EEG, EMG, movement monitoring, cognitive assessment, device follow-up, and connected diagnostic services.

These buyers prioritize compact equipment, predictable reimbursement, low staffing requirements, rapid training, and efficient report generation. Cloud-based systems that allow clinicians to review studies across several offices are especially relevant.

Home Healthcare and Remote Monitoring Providers

Home healthcare and remote monitoring providers accounted for approximately USD 0.53 billion in 2025 and represent the fastest-growing end-user segment. Their role is expanding in seizure surveillance, post-stroke rehabilitation, movement monitoring, remote programming, and chronic neurological disease management.

Commercial scalability will depend on patient onboarding, caregiver support, connectivity reliability, device logistics, data review, and escalation protocols. Vendors that provide operational support will be better positioned than those requiring providers to construct the entire workflow independently.

Rehabilitation Hospitals, Skilled Nursing Facilities, and Therapy Providers

Rehabilitation hospitals, skilled nursing facilities, and therapy providers represented approximately USD 0.35 billion in 2025. These organizations use connected gait systems, robotic rehabilitation, functional electrical stimulation, smart orthoses, cognitive rehabilitation, and home-transition platforms.

The segment is expected to grow as providers face pressure to demonstrate functional outcomes and maintain therapeutic continuity after discharge.

 

By Technology Type

Connected Implantable Systems

Connected implantable systems accounted for approximately 35% of 2025 market revenue. These systems include wireless or telemetry-enabled DBS, RNS, VNS, neural sensing, and implantable stimulation technologies. High selling prices, replacement cycles, and long-term programming support make this the largest technology type by value.

Wireless and Wearable Sensor Technologies

Wireless and wearable sensor technologies represented approximately 25% of the market. Bluetooth, Wi-Fi, cellular, and proprietary wireless protocols are used to transmit EEG, movement, gait, tremor, sleep, activity, and event information.

These technologies lead the market by unit volume and are expected to gain share as home monitoring expands.

Cloud-Connected and AI-Assisted Technologies

Cloud-connected and AI-assisted technologies accounted for approximately 18% of 2025 revenue. They support remote EEG review, automated seizure assessment, movement analysis, clinical prioritization, digital biomarkers, and enterprise data management.

This is expected to be the fastest-growing technology type through 2035, although adoption will depend on validation, cybersecurity, interoperability, and clinician trust.

Remote Programming and Interoperable Device Technologies

Remote programming and interoperable-device technologies represented approximately 14% of the market. They include secure patient controllers, clinician programming platforms, data gateways, remote therapy-management systems, and interfaces connecting neurological devices with broader clinical infrastructure.

Remote programming has particular value in movement disorders because it can reduce travel for patients who have substantial mobility limitations.

Brain-Computer Interface and Connected Neuroprosthetic Technologies

Brain-computer interface and connected neuroprosthetic technologies accounted for approximately 8% of 2025 market revenue, primarily through research systems, clinical-use neurointerfaces, rehabilitation interfaces, and commercially available non-invasive technologies.

The current revenue base is limited, but the category has considerable long-term potential. Clinical adoption will depend on durability, signal stability, surgical risk, training requirements, cybersecurity, coverage, and demonstrable functional benefit.

 

Regional Insights: Where the Market Is Growing Fastest

The U.S. Connected Neurology Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs according to population size, age distribution, neurological disease burden, academic neuroscience capacity, specialist concentration, hospital infrastructure, broadband access, payer mix, research activity, and adoption of home-based monitoring.

The South represented the largest regional market in 2025, while the West is expected to record the fastest growth through 2035. The Northeast remains the most academically concentrated and evidence-intensive market, while the Midwest provides a strong base of neuromodulation expertise, established hospital networks, and underserved rural demand.

South

The South accounted for an estimated USD 1.58 billion in 2025 and is projected to reach approximately USD 5.25 billion by 2035, representing a CAGR of about 12.76%. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and the District of Columbia.

Regional leadership is supported by a large and growing population, substantial stroke and chronic-disease burden, expanding hospital systems, high numbers of older adults, and significant urban-rural disparities in neurological access.

Texas is the largest state market in the South. Houston, Dallas-Fort Worth, Austin, and San Antonio contain major academic centers, integrated health systems, neuroscience institutes, rehabilitation networks, and advanced neurosurgical programs. The state represents a significant opportunity for connected EEG, remote neurocritical-care support, DBS, epilepsy devices, and home neurological monitoring. Its extensive rural geography also supports remote programming and hub-and-spoke neurology models.

Florida is another major market because of its large older population and high demand for Parkinson’s disease management, cognitive assessment, stroke rehabilitation, and neuromodulation. South Florida, Tampa, Orlando, Jacksonville, and Gainesville contain high-volume neurological centers. Connected technologies that reduce repeat travel are particularly relevant for older patients and caregivers.

North Carolina has a strong combination of academic neuroscience, clinical research, health-system consolidation, and technology development. The Research Triangle supports clinical trials and digital health partnerships, while major provider systems create demand for enterprise neurological monitoring.

Georgia and Tennessee benefit from large metropolitan referral centers in Atlanta, Nashville, and Memphis. These cities support advanced epilepsy, movement-disorder, stroke, neurosurgery, and rehabilitation programs. Nashville’s healthcare-services ecosystem also creates opportunities for connected-neurology companies seeking partnerships with multi-state provider organizations.

Virginia, Maryland, Delaware, and the District of Columbia have sophisticated provider networks and proximity to federal research, regulatory, military-health, and academic institutions. The Baltimore-Washington corridor is especially important for neurotechnology research, brain-computer interfaces, rehabilitation, and complex neurological care.

South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia, and Oklahoma have substantial unmet need. These states include communities with elevated stroke burden, lower specialist density, transportation limitations, and reduced access to advanced epilepsy or movement-disorder programs.

The opportunity in these states is not limited to premium academic-center technology. Portable EEG, remote specialist review, connected rehabilitation, and simplified home-monitoring platforms may have greater practical value than complex systems requiring extensive on-site infrastructure.

The South will remain the largest regional market through 2035. Growth will be supported by health-system expansion, hospital consolidation, increased adoption of remote neurological services, aging demographics, and broader deployment of connected devices beyond flagship academic centers.

West

The West represented approximately USD 1.27 billion in 2025 and is expected to reach USD 5.05 billion by 2035, reflecting an estimated CAGR of 14.80%. The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

The West is expected to record the fastest growth because it combines large population markets, rapid demographic expansion, early technology adoption, venture-backed neurotechnology development, and strong interest in digitally enabled care.

California is the region’s largest state market and one of the most strategically important connected-neurology markets nationally. The state has historically had the country’s largest absolute epilepsy population and contains a dense network of academic medical centers, neurological institutes, technology companies, medical-device developers, and digital health investors.

Northern California is especially important for point-of-care EEG, artificial intelligence, wearable neurological monitoring, and brain-computer interface development. Southern California supports major movement-disorder programs, stroke networks, rehabilitation systems, and neurosurgical centers. California also serves as an early-adoption market for technologies that combine medical devices with cloud software.

Washington and Oregon have strong integrated delivery networks and high adoption of connected-care models. Seattle’s research and technology ecosystem supports neurology innovation, while Portland and other regional centers provide sophisticated neurological and rehabilitation services. Oregon also has a comparatively high Parkinson’s disease mortality burden among older adults, strengthening demand for movement-disorder management and longitudinal monitoring.

Arizona and Nevada are high-growth markets because of rapid population expansion and increasing numbers of older residents. Phoenix, Tucson, Las Vegas, and Reno are expanding specialty-care infrastructure. These states are attractive for DBS, tremor monitoring, cognitive assessment, stroke rehabilitation, and connected home-care technologies.

Colorado and Utah have research-oriented medical centers, growing health systems, and strong digital-health adoption. Utah recorded the highest state-level Parkinson’s disease mortality rate among adults age 65 and older in 2024, reinforcing the need for movement-disorder services and remote follow-up. Colorado is well positioned for clinical partnerships involving wearable sensors, home rehabilitation, and interoperable neurological data.

New Mexico, Idaho, Montana, and Wyoming are smaller markets but have large rural catchment areas and limited specialist density. Connected devices can support regional referral networks by allowing local facilities to acquire neurological data while specialists review it remotely.

Alaska and Hawaii have distinct geographic access challenges. Patients may need air travel or long-distance transportation to reach tertiary neurological centers. Portable neurodiagnostics, home monitoring, and remote programming can therefore generate substantial care-delivery value even where absolute device volumes are lower.

The West’s competitive importance extends beyond current revenue. Many next-generation neural-interface, wearable, and AI companies are headquartered or clinically connected to the region. As these technologies move from research into routine care, the West is expected to gain national market share.

Northeast

The Northeast accounted for an estimated USD 1.09 billion in 2025 and is projected to reach approximately USD 3.63 billion by 2035, representing a CAGR of 12.78%. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, Vermont, New Hampshire, and Rhode Island.

The Northeast has the country’s highest concentration of academic neuroscience programs relative to its population. It is a major market for advanced epilepsy monitoring, DBS, responsive neurostimulation, neurocritical-care technology, clinical trials, AI-supported diagnostics, and brain-computer interface research.

New York is the largest state market in the region. New York City contains multiple nationally recognized neuroscience programs, high-volume epilepsy centers, major stroke networks, and advanced neurosurgical capabilities. Upstate New York provides a separate opportunity for remote neurology because patients outside metropolitan areas may face longer travel distances.

Massachusetts is highly influential despite its smaller population. Boston’s academic hospitals, engineering institutions, biotechnology companies, and medical-device ecosystem make the state a leading environment for early clinical evaluation. Technologies adopted by major Boston neuroscience programs can influence clinical evidence and purchasing decisions nationally.

Pennsylvania combines large urban markets in Philadelphia and Pittsburgh with extensive rural areas. The state supports high procedure volumes in epilepsy surgery, neuromodulation, stroke treatment, rehabilitation, and neurodiagnostics. Connected systems can link tertiary centers with community hospitals and outpatient neurology practices.

New Jersey and Connecticut benefit from dense healthcare infrastructure, strong commercial insurance coverage, and proximity to major academic centers. These states are attractive for premium implantable systems, ambulatory neurology platforms, and home-monitoring programs.

Maine has one of the highest Parkinson’s disease mortality rates among older adults, while Vermont and New Hampshire have aging populations and rural access constraints. Remote programming, wearable movement tracking, and connected EEG can help extend specialist services across northern New England.

Rhode Island is a smaller market but benefits from an academically concentrated provider environment and proximity to Boston. The state can serve as a focused adoption market for integrated neurological technology.

Procurement in the Northeast is evidence-intensive. Academic and integrated health systems often require comparative clinical data, cybersecurity documentation, implementation planning, health-economic evidence, and interoperability review. Sales cycles may be longer, but successful adoption can produce strong reference accounts and national clinical influence.

Midwest

The Midwest represented approximately USD 0.92 billion in 2025 and is expected to reach USD 3.16 billion by 2035, reflecting a CAGR of approximately 13.13%. The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

The Midwest has an established base of neurology, neurosurgery, neurophysiology, rehabilitation, and medical-device expertise. Regional demand is supported by major academic centers, large community hospital networks, significant chronic-disease burden, and broad rural catchment areas.

Illinois is the region’s largest state market, led by Chicago’s academic medical centers, neuroscience institutes, pediatric hospitals, and integrated health systems. The market supports connected EEG, implantable neuromodulation, neurocritical-care monitoring, and rehabilitation technology.

Ohio has a strong neurological and neurosurgical infrastructure across Cleveland, Columbus, Cincinnati, and other metropolitan areas. Large referral systems create demand for high-value implants, epilepsy monitoring, stroke technology, and enterprise device integration.

Michigan provides a substantial procedure base across Detroit, Ann Arbor, Grand Rapids, and regional health systems. Movement disorders, epilepsy, stroke, and post-acute rehabilitation are important applications. Connected platforms can help health systems coordinate neurological care across urban and rural service areas.

Minnesota is strategically important because of its medical-device heritage and concentration of clinical and engineering expertise. The state supports neuromodulation innovation, device development, clinical research, and integrated-care adoption.

Indiana, Wisconsin, Missouri, and Iowa provide stable demand across hospital neurodiagnostics, ambulatory EEG, DBS, stroke rehabilitation, and home monitoring. Indianapolis, Milwaukee, Madison, St. Louis, Kansas City, and Iowa City contain important specialty-care centers.

Kansas and Nebraska have comparatively high Parkinson’s disease mortality rates among older adults. These states also have dispersed rural populations, creating demand for remote movement-disorder care, connected rehabilitation, and portable neurodiagnostic equipment.

North Dakota and South Dakota are smaller markets by revenue but represent strong use cases for tele-neurology and hub-and-spoke specialist models. Regional medical centers can use connected systems to support patients who would otherwise travel long distances for EEG interpretation, implant follow-up, or movement-disorder assessment.

The Midwest is expected to remain a durable market for established device categories while recording faster growth in remote monitoring and connected care. Vendors that provide dependable service, clinical education, cost-effective contracting, and multi-site implementation support will be well positioned.

 

Key Market Players

The U.S. Connected Neurology Devices Competitive Landscape is fragmented across implantable neuromodulation, neurodiagnostics, wearable monitoring, rehabilitation, digital biomarkers, and brain-computer interfaces.

Medtronic, Abbott, Boston Scientific, NeuroPace, and LivaNova have strong positions in high-value implantable neurological therapy. Natus Medical, Nihon Kohden, Cadwell, Compumedics, Ceribell, Masimo, GE HealthCare, and Philips participate in neurological monitoring, EEG, hospital infrastructure, and physiological data systems.

Zeto, Empatica, BioSerenity, Rune Labs, BrainScope, and Neuroelectrics compete through wearable acquisition, digital biomarkers, portable diagnostics, or software-enabled neurological assessment. BrainsWay, Magstim, and electroCore participate in non-invasive or external neuromodulation. Synchron, Precision Neuroscience, and Blackrock Neurotech are strategically important in the developing brain-computer interface and neural-interface ecosystem.

Some of the key players in the U.S. Connected Neurology Devices industry are:

• Medtronic
• Abbott Laboratories
• Boston Scientific Corporation
• NeuroPace
• LivaNova
• Ceribell
• Natus Medical
• Nihon Kohden America
• Cadwell Industries
• Compumedics
• Masimo
• GE HealthCare
• Philips Healthcare
• Zeto
• Empatica
• BioSerenity
• Rune Labs
• BrainScope
• Neuroelectrics
• BrainsWay
• Magstim
• electroCore
• Synchron
• Precision Neuroscience
• Blackrock Neurotech

Competition is becoming platform-based. Large medtech companies can combine implants, patient controllers, clinician programmers, service networks, training, regulatory expertise, and hospital contracting. Specialist manufacturers compete by solving high-value workflow problems such as rapid EEG access, remote interpretation, wearable seizure detection, digital Parkinson’s measurement, or neural-signal acquisition.

Market share through 2035 will be influenced by FDA approvals, clinical evidence, cybersecurity performance, reimbursement integration, software quality, hospital interoperability, data usability, and post-sale service. Manufacturers that can reduce specialist workload while improving clinical visibility will be positioned to defend premium pricing.

 

Recent Developments

Recent developments in the U.S. Connected Neurology Devices Market demonstrate movement toward sensing-enabled therapy, remote care, AI-supported diagnostics, and clinically viable neural interfaces.

In February 2025, the FDA approved an adaptive deep brain stimulation programming feature for a Medtronic DBS platform. The approval was strategically important because it moved adaptive stimulation from experimental use into a commercial U.S. neurological therapy environment. The feature allows compatible systems to adjust stimulation using detected brain signals, reinforcing the market shift toward closed-loop neuromodulation.

Abbott has continued to strengthen its connected movement-disorder portfolio through rechargeable DBS technology and remote programming. Its NeuroSphere Virtual Clinic allows compatible neuromodulation patients to connect with clinicians through secure video and remote programming capabilities. This model is particularly relevant for patients who live far from implanting centers or have difficulty traveling because of motor impairment.

Connected EEG has also progressed rapidly. Ceribell’s point-of-care EEG platform combines rapid bedside deployment, remote neurological access, and cloud-based AI analysis. Its Clarity software estimates seizure burden at frequent intervals, allowing clinicians to prioritize patients with suspected ongoing seizure activity. Subsequent expansion of the platform into additional neurological assessment areas demonstrates how connected EEG manufacturers can develop new software value on top of an installed hardware base.

Portable and ambulatory EEG companies are increasing emphasis on easier sensor application, wireless acquisition, cloud review, and home deployment. This is shifting portions of EEG testing away from specialized laboratory environments and creating opportunities for community hospitals and outpatient neurology practices.

In March 2025, a temporary cortical electrode developed by Precision Neuroscience received U.S. clearance for recording, monitoring, and stimulating electrical activity at the brain surface for up to 30 days. Although this does not represent full commercial approval of a permanent BCI, it demonstrates regulatory progress in high-density neural interfaces and may support clinical research involving communication, movement, mapping, and neuroprosthetic control.

The FDA’s framework for implanted brain-computer interfaces continues to shape development of systems intended for patients with paralysis or amputation. Several companies are conducting or preparing clinical programs involving implanted neural interfaces. Commercial contribution remains limited in the current market, but successful pivotal studies could create a high-value category during the later forecast period.

Cybersecurity requirements have become more stringent. The FDA’s updated February 2026 cybersecurity guidance emphasizes secure design, labeling, documentation, lifecycle vulnerability management, and compliance obligations for connected medical devices. Neurology manufacturers must increasingly plan software updates, maintain software bills of materials, address vulnerabilities, and demonstrate that connectivity risks have been controlled.

Medicare’s remote-monitoring framework continues to support commercial development by broadly covering qualifying remote physiologic monitoring for acute and chronic conditions. Neurology companies are working to translate neurological measurements into workflows that meet clinical, documentation, and billing requirements.

Partnership activity is also increasing. Device manufacturers are collaborating with academic medical centers, artificial-intelligence companies, rehabilitation networks, and digital health platforms. These collaborations can accelerate algorithm validation, expand clinical datasets, and improve integration into real-world neurological care.

The next phase of market development is expected to include broader use of adaptive stimulation, remotely supported implant management, cloud-based EEG networks, multimodal movement monitoring, home neurological rehabilitation, and neural interfaces with more durable signal acquisition.

 

Conclusion

The U.S. Connected Neurology Devices Market Size & Share is positioned for sustained expansion from approximately USD 4.86 billion in 2025 to USD 17.09 billion by 2035, supported by a CAGR of 13.40% during the forecast period.

The market’s growth is grounded in the high burden of epilepsy, stroke, Parkinson’s disease, Alzheimer’s disease, paralysis, and other chronic neurological conditions. Demand is further supported by limited specialist access, the need for longitudinal disease measurement, increasing use of home-based care, and rapid development of sensing-enabled neuromodulation.

Connected implantable neuromodulation will remain the largest revenue category, while wearable neurological monitoring, AI-supported neurodiagnostics, and cloud-connected care platforms are expected to grow more rapidly. Epilepsy and seizure management will remain the largest application, with movement disorders recording strong expansion through adaptive DBS, remote programming, and digital motor assessment.

Hospitals and health systems will continue to control the largest share of purchasing, particularly for implants, point-of-care EEG, neurocritical monitoring, and enterprise platforms. Home healthcare and remote monitoring will represent the fastest-growing end-user channel as neurological care becomes less dependent on frequent facility visits.

The South will remain the largest regional market because of its population size, aging demographics, neurological disease burden, and expanding hospital infrastructure. The West will record the fastest growth due to technology development, venture investment, early digital adoption, and strong neurotechnology ecosystems. The Northeast will remain influential in evidence generation and advanced clinical adoption, while the Midwest will provide a stable procedural base and significant opportunity for remote neurological access.

For manufacturers and investors, the central opportunity is not simply to connect an existing neurological device to the internet. Sustainable value will come from connecting the device to a clinically actionable workflow. Technologies must help clinicians detect deterioration earlier, interpret neurological information faster, personalize therapy, reduce travel, extend specialist capacity, or document measurable recovery.

Companies that combine differentiated hardware with validated algorithms, secure connectivity, reimbursement support, interoperability, and real-world clinical evidence will define the competitive direction of the U.S. Connected Neurology Devices Market through 2035.

 

TABLE OF CONTENT

1. U.S. Connected Neurology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Connected Medical Device Inclusion Criteria
1.2.2. Neurological Device and Software Boundary
1.2.3. Commercially Available and Emerging Technology Coverage
1.2.4. Market Exclusions
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Bottom-Up Market Sizing Methodology
1.3.6. Top-Down Market Validation Methodology
1.3.7. Analytical Frameworks & Forecasting Models
1.3.8. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Connected Neurology Device Manufacturers
1.6.2. Neurotechnology Software and AI Developers
1.6.3. Sensor, Electrode, Semiconductor and Component Suppliers
1.6.4. Contract Manufacturing and Device Integration Partners
1.6.5. Hospitals and Integrated Delivery Networks
1.6.6. Academic Neuroscience and Specialty Neurology Centers
1.6.7. Ambulatory Neurology Practices and Diagnostic Centers
1.6.8. Rehabilitation Hospitals and Therapy Providers
1.6.9. Home Healthcare and Remote Monitoring Providers
1.6.10. Group Purchasing Organizations and Specialty Distributors
1.6.11. Payers, Regulators and Clinical Decision-Makers
1.6.12. Patients, Caregivers and Advocacy Organizations

What this section provides: This section defines the U.S. connected neurology devices market boundary, study scope, methodology, assumptions and stakeholder ecosystem so clients understand how implantable, diagnostic, wearable, rehabilitation, software-enabled and remotely connected neurological technologies are measured and validated.

2. U.S. Connected Neurology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size and Growth Summary, 2021–2035
2.8. Leading Product Category, 2025
2.9. Fastest-Growing Product Category, 2026–2035
2.10. Leading Clinical Application, 2025
2.11. Fastest-Growing Clinical Application, 2026–2035
2.12. Leading End-User Segment, 2025
2.13. Fastest-Growing End-User Segment, 2026–2035
2.14. Leading Technology Type, 2025
2.15. Fastest-Growing Technology Type, 2026–2035
2.16. Leading Procurement Channel, 2025
2.17. Regional Market Leadership, 2025
2.18. Fastest-Growing U.S. Region, 2026–2035
2.19. High-Growth Opportunity Areas
2.20. Critical Market Risks and Strategic Watchpoints

What this section provides: This section gives decision-makers a concise view of market size, growth direction, segment leadership, regional performance, competitive intensity, emerging risks and priority opportunity areas in the U.S. connected neurology devices industry.

3. U.S. Connected Neurology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Burden of Chronic Neurological Disorders
3.1.2. Expansion of Longitudinal Neurological Monitoring
3.1.3. Limited Access to Neurologists and Subspecialists
3.1.4. Transition from Subjective Assessment to Objective Digital Biomarkers
3.1.5. Growth of Connected and Adaptive Neuromodulation
3.1.6. Rising Demand for Point-of-Care and Rapid-Response EEG
3.1.7. Expansion of Remote Device Programming and Virtual Neurology Care
3.1.8. Growth of Home-Based Neurological Monitoring
3.1.9. Increasing Adoption of AI-Assisted Neurological Diagnostics
3.1.10. Hospital Demand for Neurology Workflow Efficiency
3.1.11. Aging U.S. Population and Increasing Neurodegenerative Disease Burden
3.1.12. Expansion of Stroke Rehabilitation and Post-Acute Neurological Care

3.2. Restraints and Their Impact Analysis
3.2.1. High Cost of Implantable and Advanced Neurotechnology Systems
3.2.2. Inconsistent Reimbursement Across Connected Neurology Applications
3.2.3. Limited Standardization of Neurological Digital Biomarkers
3.2.4. Cybersecurity and Patient Data Privacy Risks
3.2.5. Interoperability Limitations Across Devices and Clinical Systems
3.2.6. Clinician Alert Fatigue and Data-Review Burden
3.2.7. Patient Adherence and Device Usability Limitations
3.2.8. Rural Broadband and Digital Access Constraints
3.2.9. Lengthy Clinical Validation and Regulatory Approval Requirements
3.2.10. Uncertain Long-Term Evidence for Emerging Neurotechnology

3.3. Opportunities and Their Impact Analysis
3.3.1. Adaptive and Closed-Loop Deep Brain Stimulation
3.3.2. Connected Epilepsy Diagnosis and Seizure Management
3.3.3. Remote Programming of Implantable Neurological Devices
3.3.4. AI-Enabled Point-of-Care EEG Deployment
3.3.5. Wearable Parkinson’s Disease and Movement Monitoring
3.3.6. Home-Based Stroke and Neurological Rehabilitation
3.3.7. Digital Biomarker Integration in Neurological Clinical Trials
3.3.8. Brain-Computer Interfaces and Connected Neuroprosthetics
3.3.9. Enterprise Neurology Data Platforms
3.3.10. Rural and Community Hospital Neurology Networks
3.3.11. Pediatric Connected Neurology Applications
3.3.12. Recurring Software, Monitoring and Data-Service Revenue Models

3.4. Challenges and Their Impact Analysis
3.4.1. Converting Neurological Data into Clinically Actionable Information
3.4.2. Integrating Connected Devices into Existing Neurology Workflows
3.4.3. Managing False Alerts and Algorithmic Error
3.4.4. Demonstrating Health-Economic Value to Hospital Buyers
3.4.5. Maintaining Secure Software Across the Device Lifecycle
3.4.6. Scaling Clinical Training and Technical Support
3.4.7. Supporting Patients with Cognitive or Physical Limitations

3.5. Patent & Innovation Analysis, 2021–2025
3.5.1. Neuromodulation Patent Trends
3.5.2. EEG and Neural-Signal Acquisition Patent Trends
3.5.3. Wearable Neurological Sensor Patent Trends
3.5.4. Brain-Computer Interface Patent Trends
3.5.5. AI and Digital Biomarker Patent Trends

3.6. Clinical Workflow Economics Analysis
3.6.1. Neurological Diagnostic Turnaround Economics
3.6.2. Specialist Time and Clinical Review Economics
3.6.3. Remote Programming and Travel-Avoidance Economics
3.6.4. Inpatient-to-Home Monitoring Economics
3.6.5. Neurorehabilitation Productivity Economics
3.6.6. Emergency Department and Intensive Care Workflow Impact

3.7. Hospital Capital Procurement Behavior Analysis
3.7.1. Capital Equipment Versus Subscription Procurement
3.7.2. Implantable Device Contracting and Vendor Standardization
3.7.3. Cybersecurity and IT Committee Involvement
3.7.4. Clinical Champion and Neuroscience Service-Line Influence
3.7.5. Total Cost of Ownership Assessment
3.7.6. Evidence and Outcomes Requirements

What this section provides: This section explains the clinical, commercial, reimbursement, technological and operational forces shaping demand, helping clients evaluate growth opportunities, adoption barriers and execution risks across the U.S. connected neurology device ecosystem.

4. U.S. Connected Neurology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.3.1. Implantable Neuromodulation Pricing
4.3.2. Neurodiagnostic Capital Equipment Pricing
4.3.3. Disposable Electrode and Sensor Pricing
4.3.4. Wearable Monitoring Device Pricing
4.3.5. Software Subscription and Data-Service Pricing
4.3.6. Service, Maintenance and Remote Support Pricing

4.4. Value Chain & Supply Chain Analysis
4.4.1. Research and Product Development
4.4.2. Electronic Component and Sensor Sourcing
4.4.3. Implantable Component Manufacturing
4.4.4. Software and Algorithm Development
4.4.5. Device Assembly and Quality Control
4.4.6. Regulatory Approval and Clinical Validation
4.4.7. Distribution, Implementation and Clinical Training
4.4.8. Postmarket Surveillance and Software Maintenance

4.5. Impact of Digitalization and Connected Neurology
4.5.1. Cloud-Based Neurological Data Management
4.5.2. Remote Patient Monitoring
4.5.3. Remote Programming and Virtual Device Clinics
4.5.4. AI-Assisted Clinical Prioritization
4.5.5. Digital Biomarkers and Longitudinal Neurology Data

4.6. Application & Innovation Landscape
4.6.1. Connected Epilepsy Care
4.6.2. Connected Movement-Disorder Care
4.6.3. Stroke and Neurocritical Monitoring
4.6.4. Connected Neurorehabilitation
4.6.5. Neurodegenerative Disease Monitoring
4.6.6. Brain-Computer Interfaces and Neuroprosthetics

4.7. FDA Regulatory Framework Analysis
4.7.1. Premarket Approval Pathway
4.7.2. 510(k) Premarket Notification Pathway
4.7.3. De Novo Classification Pathway
4.7.4. Breakthrough Devices Program
4.7.5. Software as a Medical Device Requirements
4.7.6. AI-Enabled Device Regulatory Considerations
4.7.7. Clinical Investigation and Early Feasibility Study Requirements
4.7.8. Postmarket Surveillance and Medical Device Reporting

4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Implantable Neuromodulation Reimbursement
4.8.2. EEG and Neurodiagnostic Reimbursement
4.8.3. Remote Physiologic Monitoring
4.8.4. Remote Therapeutic Monitoring
4.8.5. Device Programming and Follow-Up Reimbursement
4.8.6. Inpatient, Outpatient and Physician Payment Dynamics
4.8.7. Coverage Evidence and Medical-Necessity Requirements

4.9. Connected Medical Device Cybersecurity Framework
4.9.1. Secure Product Development Requirements
4.9.2. Software Bill of Materials
4.9.3. Authentication and Access Control
4.9.4. Vulnerability Monitoring and Software Updates
4.9.5. Hospital Cybersecurity Procurement Review

4.10. Data Privacy, Ownership and Interoperability Analysis
4.10.1. HIPAA and Patient Data Protection
4.10.2. Device-Generated Data Ownership
4.10.3. Electronic Health Record Integration
4.10.4. Application Programming Interfaces
4.10.5. Neurological Data Portability and Standardization

4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Initiatives and Public Health Programs
4.13. Impact of Escalating Geopolitical Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.14.1. Clinical Evidence Assessment
4.14.2. Patient-Safety Assessment
4.14.3. Cybersecurity Assessment
4.14.4. Financial and Reimbursement Assessment
4.14.5. Workflow and Staffing Assessment
4.14.6. Enterprise Scalability Assessment

What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, cybersecurity, privacy, interoperability, supply chains, digital adoption and hospital procurement dynamics.

5. U.S. Connected Neurology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)

5.2. Connected Implantable Neuromodulation Devices
5.2.1. Deep Brain Stimulation Systems
5.2.2. Adaptive and Closed-Loop Deep Brain Stimulation Systems
5.2.3. Responsive Neurostimulation Systems
5.2.4. Vagus Nerve Stimulation Systems
5.2.5. Implantable Cortical Stimulation Systems
5.2.6. Sensing-Enabled Neurostimulators
5.2.7. Patient Controllers and Clinical Programmers
5.2.8. Remote Implant Programming Platforms

5.3. Connected Neurodiagnostic and Monitoring Systems
5.3.1. Conventional Connected EEG Systems
5.3.2. Ambulatory EEG Systems
5.3.3. Point-of-Care and Rapid-Response EEG Systems
5.3.4. Wearable and Wireless EEG Systems
5.3.5. Electromyography Systems
5.3.6. Evoked-Potential Systems
5.3.7. Intraoperative Neurophysiological Monitoring Systems
5.3.8. Cerebral-Function Monitoring Systems
5.3.9. Connected Intracranial and Neurocritical Monitoring Systems
5.3.10. Electrodes, Headsets, Amplifiers and Disposable Sensors

5.4. Wearable Neurological Monitoring Devices
5.4.1. Seizure-Detection Wearables
5.4.2. Tremor and Movement-Disorder Sensors
5.4.3. Gait and Balance Monitoring Devices
5.4.4. Wearable Motor-Fluctuation Monitoring Systems
5.4.5. Cognitive and Behavioral Monitoring Devices
5.4.6. Sleep-Neurology Monitoring Devices
5.4.7. Multimodal Neurological Wearables
5.4.8. Patient Alert and Caregiver Notification Devices

5.5. Connected Neurorehabilitation and Assistive Devices
5.5.1. Robotic Neurorehabilitation Systems
5.5.2. Functional Electrical Stimulation Devices
5.5.3. Connected Exoskeletons
5.5.4. Smart Orthoses and Mobility Devices
5.5.5. Instrumented Gait and Balance Systems
5.5.6. Upper-Extremity Rehabilitation Devices
5.5.7. Cognitive and Speech Rehabilitation Devices
5.5.8. Connected Assistive Communication Devices
5.5.9. Home Neurorehabilitation Platforms

5.6. Software-Enabled Neurology Platforms and Connectivity Components
5.6.1. AI-Enabled Neurological Analysis Software
5.6.2. Remote Device-Management Platforms
5.6.3. Neurological Data Gateways
5.6.4. Digital Biomarker Platforms
5.6.5. Device-Linked Clinical Decision-Support Software
5.6.6. Interoperability and EHR Integration Software
5.6.7. Cybersecurity and Device-Lifecycle Software
5.6.8. Neurology Analytics and Population-Management Platforms

What this section provides: This section identifies which connected neurology product categories and subcategories are expected to generate the highest revenue contribution, recurring commercial value and strongest growth through 2035.

6. U.S. Connected Neurology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Application, 2021–2035 (US$ Billion)

6.2. Epilepsy and Seizure Management
6.2.1. Inpatient Epilepsy Monitoring
6.2.2. Ambulatory Epilepsy Monitoring
6.2.3. Emergency and Critical-Care Seizure Detection
6.2.4. Drug-Resistant Epilepsy Neuromodulation
6.2.5. Pediatric Epilepsy Monitoring
6.2.6. Home Seizure Detection and Caregiver Alerts
6.2.7. Post-Treatment Seizure Surveillance

6.3. Movement Disorders
6.3.1. Parkinson’s Disease
6.3.2. Essential Tremor
6.3.3. Dystonia
6.3.4. Dyskinesia and Motor-Fluctuation Monitoring
6.3.5. Gait Disturbance and Freezing-of-Gait Monitoring
6.3.6. Connected Deep Brain Stimulation Management
6.3.7. Remote Movement-Disorder Assessment

6.4. Stroke and Neurocritical Care
6.4.1. Acute Stroke Monitoring
6.4.2. Intensive Care Neurological Monitoring
6.4.3. Non-Convulsive Seizure Detection
6.4.4. Cerebral-Function Monitoring
6.4.5. Neurological Deterioration Surveillance
6.4.6. Post-Stroke Rehabilitation
6.4.7. Post-Discharge Stroke Recovery Monitoring

6.5. Neurodegenerative and Cognitive Disorders
6.5.1. Alzheimer’s Disease and Dementia
6.5.2. Parkinson’s Disease Progression Monitoring
6.5.3. Multiple Sclerosis
6.5.4. Amyotrophic Lateral Sclerosis
6.5.5. Cognitive Decline Monitoring
6.5.6. Speech, Sleep and Activity Biomarkers
6.5.7. Decentralized Neurology Clinical Trials

6.6. Paralysis, Neurorehabilitation and Other Neurological Applications
6.6.1. Spinal Cord Injury
6.6.2. Traumatic Brain Injury
6.6.3. Cerebral Palsy
6.6.4. Neuromuscular Disorders
6.6.5. Peripheral Nerve Impairment
6.6.6. Severe Communication Disability
6.6.7. Neuroprosthetic Control and Brain-Computer Interfaces
6.6.8. Chronic Pain and Other Neuromodulation Applications

What this section provides: This section helps clients understand connected-device demand by neurological condition and clinical use case, allowing them to prioritize applications with strong patient need, procedure growth, reimbursement relevance and technology adoption.

7. U.S. Connected Neurology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

7.2. Hospitals and Integrated Health Systems
7.2.1. Large Integrated Delivery Networks
7.2.2. Community Hospitals
7.2.3. Emergency Departments
7.2.4. Intensive Care Units
7.2.5. Hospital Epilepsy Monitoring Units
7.2.6. Hospital Stroke and Neuroscience Programs

7.3. Academic Neuroscience and Specialty Neurology Centers
7.3.1. Comprehensive Epilepsy Centers
7.3.2. Movement-Disorder Centers
7.3.3. Functional Neurosurgery Programs
7.3.4. Comprehensive Stroke Centers
7.3.5. Neurodegenerative Disease Centers
7.3.6. Brain-Computer Interface and Neurotechnology Research Centers

7.4. Ambulatory Neurology Practices and Diagnostic Centers
7.4.1. Independent Neurology Practices
7.4.2. Ambulatory EEG Providers
7.4.3. Neurophysiology Diagnostic Centers
7.4.4. Device Programming Clinics
7.4.5. Cognitive and Movement Assessment Centers

7.5. Home Healthcare and Remote Monitoring Providers
7.5.1. Home EEG Service Providers
7.5.2. Neurological Remote Patient Monitoring Providers
7.5.3. Virtual Neurology and Tele-neurology Networks
7.5.4. Home-Based Device Programming and Follow-Up Programs
7.5.5. Caregiver-Supported Monitoring Programs

7.6. Rehabilitation Hospitals, Skilled Nursing Facilities and Therapy Providers
7.6.1. Inpatient Rehabilitation Facilities
7.6.2. Outpatient Neurorehabilitation Centers
7.6.3. Skilled Nursing Facilities
7.6.4. Physical and Occupational Therapy Providers
7.6.5. Home Rehabilitation Providers
7.6.6. Veterans and Military Rehabilitation Programs

What this section provides: This section explains which care settings and customer groups are expected to drive connected-device purchasing, implantation, diagnostic testing, recurring monitoring and neurorehabilitation demand.

8. U.S. Connected Neurology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)

8.2. Connected Implantable Systems
8.2.1. Telemetry-Enabled Implantable Systems
8.2.2. Sensing-Enabled Neuromodulation Systems
8.2.3. Adaptive and Closed-Loop Systems
8.2.4. Rechargeable Implantable Systems
8.2.5. Patient-Controlled Implantable Systems
8.2.6. Remote-Programmable Implantable Systems

8.3. Wireless and Wearable Sensor Technologies
8.3.1. Bluetooth-Enabled Devices
8.3.2. Wi-Fi-Enabled Devices
8.3.3. Cellular-Connected Devices
8.3.4. Proprietary Wireless Systems
8.3.5. Accelerometer and Gyroscope Sensors
8.3.6. Wearable EEG and Electrophysiology Sensors
8.3.7. Multimodal Physiological Sensors

8.4. Cloud-Connected and AI-Assisted Technologies
8.4.1. Cloud-Based EEG Analysis
8.4.2. AI-Assisted Seizure Detection
8.4.3. AI-Assisted Movement Analysis
8.4.4. Digital Biomarker Analytics
8.4.5. Clinical Prioritization and Alerting
8.4.6. Longitudinal Neurological Data Platforms
8.4.7. Predictive Neurological Analytics

8.5. Remote Programming and Interoperable Device Technologies
8.5.1. Remote Implant Programming
8.5.2. Virtual Device Clinics
8.5.3. Patient Controllers and Connectivity Hubs
8.5.4. Electronic Health Record Integration
8.5.5. API-Enabled Neurology Platforms
8.5.6. Multi-Device Clinical Dashboards
8.5.7. Secure Device-Management Technologies

8.6. Brain-Computer Interface and Connected Neuroprosthetic Technologies
8.6.1. Implanted Cortical Interfaces
8.6.2. Endovascular Neural Interfaces
8.6.3. Non-Invasive Brain-Computer Interfaces
8.6.4. High-Density Neural Recording Systems
8.6.5. Neuroprosthetic Control Systems
8.6.6. Assistive Communication Interfaces
8.6.7. Sensory Restoration Interfaces
8.6.8. Rehabilitation Brain-Computer Interfaces

What this section provides: This section evaluates the major technology platforms shaping connected neurological care, including implantable sensing, wireless monitoring, cloud analytics, AI, remote programming, interoperability and brain-computer interfaces.

9. U.S. Connected Neurology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

9.2. Direct Hospital and Health System Procurement
9.2.1. Capital Equipment Purchases
9.2.2. Implantable Device Purchases
9.2.3. Disposable Sensor and Electrode Contracts
9.2.4. Software and Service Agreements
9.2.5. Clinical Evaluation and Value Analysis Processes

9.3. Integrated Delivery Network Enterprise Contracts
9.3.1. Multi-Hospital Vendor Standardization
9.3.2. Enterprise Neurology Platform Contracts
9.3.3. System-Wide Device and Software Bundling
9.3.4. Outcome-Based and Volume-Based Agreements
9.3.5. Cybersecurity and Interoperability Requirements

9.4. Group Purchasing Organization Contracts
9.4.1. National GPO Contracts
9.4.2. Regional GPO Contracts
9.4.3. Aggregated Hospital Purchasing
9.4.4. Contract Compliance and Vendor Access
9.4.5. Pricing and Rebate Structures

9.5. Distributor and Specialty Neurotechnology Supplier Sales
9.5.1. Medical Device Distributors
9.5.2. Neurodiagnostic Equipment Distributors
9.5.3. Rehabilitation Technology Distributors
9.5.4. Home Monitoring Equipment Suppliers
9.5.5. Technical Service and Implementation Partners

9.6. Ambulatory, Rehabilitation and Home-Care Procurement
9.6.1. Independent Neurology Practice Procurement
9.6.2. Ambulatory Diagnostic Center Procurement
9.6.3. Rehabilitation Provider Procurement
9.6.4. Remote Monitoring Service Contracts
9.6.5. Software-as-a-Service Procurement
9.6.6. Rental, Leasing and Per-Patient Models

What this section provides: This section helps clients understand how connected neurology devices are purchased in the United States, including direct hospital acquisition, IDN standardization, GPO influence, specialty distribution, software contracting and decentralized-care procurement.

10. U.S. Connected Neurology Devices Market – By Geography
10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Neurological Disease Burden Analysis
10.1.4. Regional Neuroscience Center and Hospital Infrastructure Analysis
10.1.5. Regional Neurologist and Subspecialist Access Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics
10.1.7. Regional Connected-Care and Tele-neurology Adoption
10.1.8. Regional Clinical Trial and Neurotechnology Innovation Activity

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Connected Neurology Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Connected Neurology Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Connected Neurology Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Connected Neurology Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify neurological care hubs, specialist-access gaps, clinical adoption hotspots, procurement environments and priority commercial opportunities.

11. U.S. Connected Neurology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Overall Market Share
11.1.2. Implantable Neuromodulation Market Share
11.1.3. Neurodiagnostic and EEG Market Share
11.1.4. Wearable Neurological Monitoring Market Share
11.1.5. Connected Neurorehabilitation Market Share
11.1.6. Software and Digital Neurology Platform Market Share

11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. Connectivity and Software Capability
11.3.3. U.S. Regulatory Position
11.3.4. Clinical Evidence Strength
11.3.5. Hospital and Specialist Access
11.3.6. Remote Monitoring Capability
11.3.7. Cybersecurity and Interoperability Readiness
11.3.8. Recurring Revenue Exposure

11.4. Company Profiles

11.4.1. Medtronic
11.4.2. Abbott Laboratories
11.4.3. Boston Scientific Corporation
11.4.4. NeuroPace
11.4.5. LivaNova
11.4.6. Natus Medical
11.4.7. Nihon Kohden America
11.4.8. Cadwell Industries
11.4.9. Compumedics
11.4.10. Ceribell
11.4.11. Masimo
11.4.12. GE HealthCare
11.4.13. Philips Healthcare
11.4.14. Zeto
11.4.15. Empatica
11.4.16. BioSerenity
11.4.17. Rune Labs
11.4.18. BrainScope
11.4.19. Neuroelectrics
11.4.20. BrainsWay
11.4.21. Magstim
11.4.22. electroCore
11.4.23. Synchron
11.4.24. Precision Neuroscience
11.4.25. Blackrock Neurotech

Note: Each company profile will include company overview, connected neurology device portfolio, core technologies, U.S. market strategy, financial positioning, regulatory status, clinical evidence, intellectual property, software and connectivity capabilities, partnerships, acquisitions and recent developments.

11.5. Strategic Initiatives Analysis
11.5.1. Product Launches
11.5.2. FDA Approvals and Clearances
11.5.3. Mergers and Acquisitions
11.5.4. Strategic Partnerships
11.5.5. Clinical Research Collaborations
11.5.6. Geographic and Channel Expansion
11.5.7. Software and Platform Integration

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, innovation direction and strategic intelligence on 25 major and emerging connected neurology device companies.

12. U.S. Connected Neurology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. Adaptive and Closed-Loop Neuromodulation
12.2.2. AI-Assisted Point-of-Care EEG
12.2.3. Wearable Neurological Digital Biomarkers
12.2.4. Remote Programming and Virtual Device Clinics
12.2.5. Home-Based Neurological Monitoring
12.2.6. Connected Neurorehabilitation and Robotics
12.2.7. Brain-Computer Interfaces
12.2.8. Connected Neuroprosthetics
12.2.9. Predictive Neurological Analytics
12.2.10. Multimodal Neural and Physiological Sensing

12.3. Emerging Business Trends
12.3.1. Hardware-Plus-Software Business Models
12.3.2. Subscription-Based Neurology Platforms
12.3.3. Per-Patient Monitoring Models
12.3.4. Hospital Enterprise Platform Contracting
12.3.5. Device-Enabled Clinical Services
12.3.6. Decentralized Neurological Clinical Trials
12.3.7. Value-Based and Outcome-Linked Contracting

12.4. Business Opportunities for Startups and Existing Players
12.4.1. Clinical Workflow Gaps
12.4.2. Rural Neurology Access
12.4.3. Pediatric Neurology Monitoring
12.4.4. Home Neurorehabilitation
12.4.5. Digital Biomarker Validation
12.4.6. Neurology Data Interoperability
12.4.7. Cybersecurity and Device-Lifecycle Management

12.5. Investment Prioritization Matrix
12.5.1. Market Attractiveness
12.5.2. Clinical Differentiation
12.5.3. Regulatory Risk
12.5.4. Reimbursement Readiness
12.5.5. Competitive Intensity
12.5.6. Commercial Scalability

12.6. Technology Adoption Roadmap, 2026–2035
12.7. Market Structure Evolution
12.8. Long-Term Competitive Outlook

What this section provides: This section prepares clients for future technology shifts, changes in market structure, investment opportunities, new business models and potential connected-neurology adoption scenarios through 2035.

13. U.S. Connected Neurology Devices Market: Strategic Recommendations

13.1. Recommendations for Connected Neurology Device Manufacturers
13.1.1. Prioritize Clinically Actionable Connectivity
13.1.2. Build Reimbursement-Ready Workflows
13.1.3. Strengthen Cybersecurity and Interoperability
13.1.4. Expand Clinical Evidence Generation
13.1.5. Develop Recurring Software and Service Revenue
13.1.6. Support Specialist and Patient Training

13.2. Recommendations for Hospitals and Integrated Health Systems
13.2.1. Establish Enterprise Neurology Technology Governance
13.2.2. Evaluate Total Cost of Ownership
13.2.3. Integrate Connected Devices with Clinical Workflows
13.2.4. Develop Remote Device-Management Programs
13.2.5. Strengthen Cybersecurity Review
13.2.6. Track Clinical and Economic Outcomes

13.3. Recommendations for Academic Neuroscience and Specialty Centers
13.3.1. Build Connected Neurology Centers of Excellence
13.3.2. Expand Clinical Trial Partnerships
13.3.3. Standardize Digital Neurological Endpoints
13.3.4. Develop Regional Hub-and-Spoke Networks

13.4. Recommendations for Investors and Private Equity Firms
13.4.1. Evaluate Regulatory and Reimbursement Readiness
13.4.2. Prioritize Defensible Clinical Data
13.4.3. Assess Hardware-Software Revenue Quality
13.4.4. Identify Scalable Specialist-Support Models
13.4.5. Evaluate Postmarket Cybersecurity Obligations

13.5. Recommendations for Distributors and Channel Partners
13.5.1. Develop Neurology-Specific Technical Expertise
13.5.2. Expand Implementation and Training Services
13.5.3. Support Ambulatory and Rural Provider Adoption
13.5.4. Build Recurring Consumable and Software Revenue

13.6. Recommendations for New Entrants and Startups
13.6.1. Target Defined Clinical Workflow Problems
13.6.2. Avoid Non-Actionable Data Generation
13.6.3. Engage FDA and Payers Early
13.6.4. Build Academic and Health-System Partnerships
13.6.5. Design for Enterprise Cybersecurity Requirements
13.6.6. Establish Scalable Clinical Support

13.7. Go-to-Market Strategy Considerations
13.7.1. Clinical Champion Development
13.7.2. Key Opinion Leader Engagement
13.7.3. Hospital Value Analysis Strategy
13.7.4. Reimbursement and Coding Support
13.7.5. Regional Market Prioritization
13.7.6. Direct and Distributor Channel Strategy
13.7.7. Post-Sale Clinical Support

13.8. Product Positioning and Portfolio Expansion Guidance
13.8.1. Platform Versus Standalone Device Positioning
13.8.2. Hardware and Software Bundling
13.8.3. Enterprise Integration Strategy
13.8.4. Adjacent Neurological Application Expansion
13.8.5. Home and Ambulatory Care Expansion

What this section provides: This section converts market intelligence into actionable strategy for product development, clinical evidence, commercialization, procurement, channel expansion, investment decisions and competitive differentiation.

14. U.S. Connected Neurology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Definition Limitation
14.4. Forecasting Limitation
14.5. Regulatory and Reimbursement Limitation
14.6. Emerging Technology Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer
14.9. Company and Product Information Disclaimer
14.10. Currency, Rounding and Market-Estimate Disclaimer

What this section provides: This section clarifies the report’s scope, data-use terms, market-estimation boundaries, regulatory limitations, emerging-technology assumptions, legal conditions and forecasting limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Connected Neurology Devices Market: Market Definition
TABLE 3: U.S. Connected Neurology Devices Market: Study Scope, Inclusions and Exclusions
TABLE 4: U.S. Connected Neurology Devices Market: Research Methodology Framework
TABLE 5: U.S. Connected Neurology Devices Market: Market Sizing and Forecasting Methodology
TABLE 6: U.S. Connected Neurology Devices Market: Key Assumptions
TABLE 7: U.S. Connected Neurology Devices Market: Market Ecosystem Overview
TABLE 8: U.S. Connected Neurology Devices Market: Stakeholder Analysis
TABLE 9: U.S. Connected Neurology Devices Market: Executive Summary Snapshot, 2025
TABLE 10: U.S. Connected Neurology Devices Market: Analyst Viewpoint Summary
TABLE 11: U.S. Connected Neurology Devices Market: Market Attractiveness Index
TABLE 12: U.S. Connected Neurology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 13: U.S. Connected Neurology Devices Market: Base Year Market Positioning, 2025
TABLE 14: U.S. Connected Neurology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 15: U.S. Connected Neurology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 16: U.S. Connected Neurology Devices Market: High-Growth Opportunity Areas
TABLE 17: U.S. Connected Neurology Devices Market: Drivers; Impact Analysis
TABLE 18: U.S. Connected Neurology Devices Market: Restraints; Impact Analysis
TABLE 19: U.S. Connected Neurology Devices Market: Opportunities; Impact Analysis
TABLE 20: U.S. Connected Neurology Devices Market: Challenges; Impact Analysis
TABLE 21: U.S. Connected Neurology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 22: U.S. Connected Neurology Devices Market: Clinical Workflow Economics Matrix
TABLE 23: U.S. Connected Neurology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 24: U.S. Connected Neurology Devices Market: PESTEL Analysis
TABLE 25: U.S. Connected Neurology Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. Connected Neurology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. Connected Neurology Devices Market: Value Chain Analysis
TABLE 28: U.S. Connected Neurology Devices Market: Supply Chain Analysis
TABLE 29: U.S. Connected Neurology Devices Market: Digitalization and Connected Neurology Impact
TABLE 30: U.S. Connected Neurology Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Connected Neurology Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Connected Neurology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Connected Neurology Devices Market: Connected Medical Device Cybersecurity Framework
TABLE 34: U.S. Connected Neurology Devices Market: Data Privacy, Ownership and Interoperability Analysis
TABLE 35: U.S. Connected Neurology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 36: U.S. Connected Neurology Devices Market: Government Initiatives and Public Health Programs
TABLE 37: U.S. Connected Neurology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 38: U.S. Connected Neurology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 39: U.S. Connected Neurology Devices Market: Product Category Snapshot, 2025
TABLE 40: Segment Dashboard; Definition and Scope, by Product Category
TABLE 41: U.S. Connected Neurology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 42: U.S. Connected Neurology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 43: U.S. Connected Neurology Devices Market: Connected Implantable Neuromodulation Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Connected Neurology Devices Market: Connected Neurodiagnostic and Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Connected Neurology Devices Market: Wearable Neurological Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Connected Neurology Devices Market: Connected Neurorehabilitation and Assistive Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Connected Neurology Devices Market: Software-Enabled Neurology Platforms and Connectivity Components Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Connected Neurology Devices Market: Application Snapshot, 2025
TABLE 49: Segment Dashboard; Definition and Scope, by Application
TABLE 50: U.S. Connected Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 51: U.S. Connected Neurology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 52: U.S. Connected Neurology Devices Market: Epilepsy and Seizure Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Connected Neurology Devices Market: Movement Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Connected Neurology Devices Market: Stroke and Neurocritical Care Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Connected Neurology Devices Market: Neurodegenerative and Cognitive Disorders Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Connected Neurology Devices Market: Paralysis, Neurorehabilitation and Other Neurological Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Connected Neurology Devices Market: End User Snapshot, 2025
TABLE 58: Segment Dashboard; Definition and Scope, by End User
TABLE 59: U.S. Connected Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 60: U.S. Connected Neurology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 61: U.S. Connected Neurology Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Connected Neurology Devices Market: Academic Neuroscience and Specialty Neurology Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Connected Neurology Devices Market: Ambulatory Neurology Practices and Diagnostic Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Connected Neurology Devices Market: Home Healthcare and Remote Monitoring Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Connected Neurology Devices Market: Rehabilitation Hospitals, Skilled Nursing Facilities and Therapy Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Connected Neurology Devices Market: Technology Type Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 68: U.S. Connected Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 69: U.S. Connected Neurology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 70: U.S. Connected Neurology Devices Market: Connected Implantable Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Connected Neurology Devices Market: Wireless and Wearable Sensor Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Connected Neurology Devices Market: Cloud-Connected and AI-Assisted Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Connected Neurology Devices Market: Remote Programming and Interoperable Device Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Connected Neurology Devices Market: Brain-Computer Interface and Connected Neuroprosthetic Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Connected Neurology Devices Market: Procurement Channel Snapshot, 2025
TABLE 76: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 77: U.S. Connected Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 78: U.S. Connected Neurology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 79: U.S. Connected Neurology Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Connected Neurology Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Connected Neurology Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Connected Neurology Devices Market: Distributor and Specialty Neurotechnology Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Connected Neurology Devices Market: Ambulatory, Rehabilitation and Home-Care Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Connected Neurology Devices Market: Regional Snapshot, 2025
TABLE 85: Segment Dashboard; Definition and Scope, by Region
TABLE 86: U.S. Connected Neurology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 87: U.S. Connected Neurology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 88: U.S. Connected Neurology Devices Market: Regional Neurological Disease Burden and Specialist Access Matrix
TABLE 89: U.S. Connected Neurology Devices Market: Regional Neuroscience Infrastructure and Procurement Matrix
TABLE 90: West Region U.S. Connected Neurology Devices Market: Regional Overview and Trends
TABLE 91: West Region U.S. Connected Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 92: West Region U.S. Connected Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Connected Neurology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Connected Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Connected Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. Connected Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Connected Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 98: California Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 99: Washington Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 100: Arizona Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 101: Colorado Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 102: Oregon Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 103: Utah Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 104: Nevada Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 105: New Mexico Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 106: Idaho Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 107: Montana Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 108: Wyoming Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 109: Alaska Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 110: Hawaii Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. Connected Neurology Devices Market: Regional Overview and Trends
TABLE 112: Northeast Region U.S. Connected Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 113: Northeast Region U.S. Connected Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Connected Neurology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Connected Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Connected Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: Northeast Region U.S. Connected Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 118: Northeast Region U.S. Connected Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 119: New York Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 120: Massachusetts Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 121: New Jersey Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 122: Pennsylvania Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 123: Connecticut Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 124: Maine Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 125: Vermont Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 126: New Hampshire Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 127: Rhode Island Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 128: Delaware Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Connected Neurology Devices Market: Regional Overview and Trends
TABLE 130: South Region U.S. Connected Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 131: South Region U.S. Connected Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Connected Neurology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 133: South Region U.S. Connected Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Connected Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 135: South Region U.S. Connected Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. Connected Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 137: Texas Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 138: Florida Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 139: Georgia Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 140: North Carolina Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 141: Tennessee Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 142: South Carolina Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 143: Alabama Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 144: Mississippi Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 145: Louisiana Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 146: Arkansas Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 147: Kentucky Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 148: Oklahoma Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 149: Virginia Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 150: Maryland Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 151: West Virginia Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. Connected Neurology Devices Market: Regional Overview and Trends
TABLE 153: Midwest Region U.S. Connected Neurology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 154: Midwest Region U.S. Connected Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 155: Midwest Region U.S. Connected Neurology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 156: Midwest Region U.S. Connected Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Connected Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 158: Midwest Region U.S. Connected Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. Connected Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 160: Illinois Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 161: Ohio Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 162: Michigan Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 163: Minnesota Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 164: Indiana Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 165: Wisconsin Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 166: Missouri Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 167: Iowa Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 168: Kansas Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 169: Nebraska Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 170: North Dakota Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 171: South Dakota Connected Neurology Devices Market, by Product Category, Application, End User, Technology Type and Procurement Channel, 2021–2035 (US$ Billion)
TABLE 172: U.S. Connected Neurology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 173: U.S. Connected Neurology Devices Market: Key Company Market Share Analysis, 2025
TABLE 174: U.S. Connected Neurology Devices Market: Company Positioning Matrix
TABLE 175: U.S. Connected Neurology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 176: U.S. Connected Neurology Devices Market: Connectivity, AI and Remote Monitoring Capability Benchmarking
TABLE 177: U.S. Connected Neurology Devices Market: Regulatory, Clinical Evidence and Reimbursement Benchmarking
TABLE 178: U.S. Connected Neurology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 179: Medtronic: Company Profile
TABLE 180: Abbott Laboratories: Company Profile
TABLE 181: Boston Scientific Corporation: Company Profile
TABLE 182: NeuroPace: Company Profile
TABLE 183: LivaNova: Company Profile
TABLE 184: Natus Medical: Company Profile
TABLE 185: Nihon Kohden America: Company Profile
TABLE 186: Cadwell Industries: Company Profile
TABLE 187: Compumedics: Company Profile
TABLE 188: Ceribell: Company Profile
TABLE 189: Masimo: Company Profile
TABLE 190: GE HealthCare: Company Profile
TABLE 191: Philips Healthcare: Company Profile
TABLE 192: Zeto: Company Profile
TABLE 193: Empatica: Company Profile
TABLE 194: BioSerenity: Company Profile
TABLE 195: Rune Labs: Company Profile
TABLE 196: BrainScope: Company Profile
TABLE 197: Neuroelectrics: Company Profile
TABLE 198: BrainsWay: Company Profile
TABLE 199: Magstim: Company Profile
TABLE 200: electroCore: Company Profile
TABLE 201: Synchron: Company Profile
TABLE 202: Precision Neuroscience: Company Profile
TABLE 203: Blackrock Neurotech: Company Profile
TABLE 204: U.S. Connected Neurology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 205: U.S. Connected Neurology Devices Market: Disruptive Technologies Impact Matrix
TABLE 206: U.S. Connected Neurology Devices Market: Emerging Business Trends
TABLE 207: U.S. Connected Neurology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 208: U.S. Connected Neurology Devices Market: Investment Prioritization Matrix
TABLE 209: U.S. Connected Neurology Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 210: U.S. Connected Neurology Devices Market: Market Structure Evolution
TABLE 211: U.S. Connected Neurology Devices Market: Long-Term Competitive Outlook
TABLE 212: U.S. Connected Neurology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 213: U.S. Connected Neurology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 214: U.S. Connected Neurology Devices Market: Strategic Recommendations for Academic Neuroscience and Specialty Centers
TABLE 215: U.S. Connected Neurology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 216: U.S. Connected Neurology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 217: U.S. Connected Neurology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 218: U.S. Connected Neurology Devices Market: Go-to-Market Strategy Considerations
TABLE 219: U.S. Connected Neurology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 220: U.S. Connected Neurology Devices Market: Scope Limitation
TABLE 221: U.S. Connected Neurology Devices Market: Data Use Limitation
TABLE 222: U.S. Connected Neurology Devices Market: Market Definition Limitation
TABLE 223: U.S. Connected Neurology Devices Market: Forecasting Limitation
TABLE 224: U.S. Connected Neurology Devices Market: Regulatory and Reimbursement Limitation
TABLE 225: U.S. Connected Neurology Devices Market: Emerging Technology Limitation
TABLE 226: U.S. Connected Neurology Devices Market: Legal Disclaimer
TABLE 227: U.S. Connected Neurology Devices Market: Third-Party Data Disclaimer
TABLE 228: U.S. Connected Neurology Devices Market: Company and Product Information Disclaimer
TABLE 229: U.S. Connected Neurology Devices Market: Currency, Rounding and Market-Estimate Disclaimer

List of Figures

FIGURE 1: U.S. Connected Neurology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Sizing and Forecasting Framework
FIGURE 4: Connected Neurology Device Ecosystem
FIGURE 5: Stakeholder Ecosystem Map
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: U.S. Connected Neurology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 8: U.S. Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 9: U.S. Connected Neurology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 10: U.S. Connected Neurology Devices Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Workflow Economics Framework
FIGURE 13: Hospital Capital Procurement Decision Framework
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: Connected Neurology Digitalization Impact Framework
FIGURE 19: FDA Regulatory Pathway Framework
FIGURE 20: CMS Reimbursement and Coverage Framework
FIGURE 21: Connected Medical Device Cybersecurity Framework
FIGURE 22: Neurological Data Privacy and Interoperability Framework
FIGURE 23: Hospital Value Analysis Committee Decision Framework
FIGURE 24: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Connected Implantable Neuromodulation Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Connected Neurodiagnostic and Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Wearable Neurological Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Connected Neurorehabilitation and Assistive Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Software-Enabled Neurology Platforms and Connectivity Components Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 32: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Epilepsy and Seizure Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Movement Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Stroke and Neurocritical Care Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Neurodegenerative and Cognitive Disorders Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Paralysis, Neurorehabilitation and Other Neurological Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 39: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Academic Neuroscience and Specialty Neurology Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Ambulatory Neurology Practices and Diagnostic Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Home Healthcare and Remote Monitoring Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Rehabilitation Hospitals, Skilled Nursing Facilities and Therapy Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Connected Implantable Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Wireless and Wearable Sensor Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Cloud-Connected and AI-Assisted Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Remote Programming and Interoperable Device Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Brain-Computer Interface and Connected Neuroprosthetic Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Distributor and Specialty Neurotechnology Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Ambulatory, Rehabilitation and Home-Care Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 60: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: U.S. Connected Neurology Devices Market: State-Level Opportunity Heat Map, 2025
FIGURE 62: West Region U.S. Connected Neurology Devices Market Share and Leading Players, 2025
FIGURE 63: West Region Market Share Analysis by State, 2025
FIGURE 64: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: California Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Washington Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Arizona Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Colorado Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Oregon Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Utah Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Nevada Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: New Mexico Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Idaho Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Montana Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Wyoming Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Alaska Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Hawaii Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Northeast Region U.S. Connected Neurology Devices Market Share and Leading Players, 2025
FIGURE 79: Northeast Region Market Share Analysis by State, 2025
FIGURE 80: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: New York Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Massachusetts Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Jersey Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Pennsylvania Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Connecticut Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Maine Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Vermont Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: New Hampshire Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Rhode Island Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Delaware Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Region U.S. Connected Neurology Devices Market Share and Leading Players, 2025
FIGURE 92: South Region Market Share Analysis by State, 2025
FIGURE 93: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Texas Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Florida Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Georgia Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: North Carolina Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Tennessee Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: South Carolina Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Alabama Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Mississippi Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Louisiana Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Arkansas Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Kentucky Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Oklahoma Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Virginia Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Maryland Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: West Virginia Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Midwest Region U.S. Connected Neurology Devices Market Share and Leading Players, 2025
FIGURE 110: Midwest Region Market Share Analysis by State, 2025
FIGURE 111: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Illinois Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Ohio Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Michigan Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Minnesota Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Indiana Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Wisconsin Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Missouri Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Iowa Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Kansas Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Nebraska Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: North Dakota Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: South Dakota Connected Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 125: Company Positioning Matrix
FIGURE 126: Key Player Product Portfolio Benchmarking
FIGURE 127: Connectivity, AI and Remote Monitoring Capability Benchmarking
FIGURE 128: Regulatory, Clinical Evidence and Reimbursement Benchmarking
FIGURE 129: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 130: Connected Neurology Device Innovation Roadmap
FIGURE 131: Adaptive and Closed-Loop Neuromodulation Adoption Roadmap
FIGURE 132: AI-Assisted Point-of-Care EEG Opportunity Map
FIGURE 133: Wearable Neurological Digital Biomarker Growth Roadmap
FIGURE 134: Remote Programming and Virtual Device Clinic Adoption Roadmap
FIGURE 135: Brain-Computer Interface and Connected Neuroprosthetic Development Roadmap
FIGURE 136: Future Market Scenario Analysis, 2026–2035
FIGURE 137: Disruptive Technologies Impact Matrix
FIGURE 138: Emerging Business Trends Matrix
FIGURE 139: Investment Prioritization Matrix
FIGURE 140: Technology Adoption Roadmap, 2026–2035
FIGURE 141: Strategic Growth Roadmap for U.S. Connected Neurology Device Companies
FIGURE 142: Go-to-Market Strategy Framework
FIGURE 143: Product Positioning and Portfolio Expansion Framework
FIGURE 144: Report Scope and Disclaimer Framework